Out“FOX”ing cancer: the implications of FOXC2 as a putative predictive biomarker for cancer immunotherapy

1

FOXC2 is an oncogenic driver linked to cancer progression, influencing tumor angiogenesis, metabolism, and epithelial-mesenchymal transition.
2

Dysregulation of FOXC2 has been associated with poor prognostic factors in various cancers, including resistance to chemotherapy and immunotherapy.
3

Recent studies suggest FOXC2 may play a role in tumor immune evasion, negatively correlating with T cell infiltration in melanoma.
4

Elevated FOXC2 expression in tumors has been linked to reduced progression-free survival in melanoma patients treated with immune checkpoint inhibitors.
5

The article emphasizes the need for further research to validate FOXC2 as a predictive biomarker for cancer immunotherapy.

1